Post a Comment Print Share on Facebook
Featured Estados Unidos Ucrania Pedro Sánchez Rusia PSOE

STATEMENT: Affidea Group appoints Frans van Houten as new member of the Supervisory Board

(Information sent by the signatory company).

- 0 reads.

STATEMENT: Affidea Group appoints Frans van Houten as new member of the Supervisory Board

(Information sent by the signatory company)

- Affidea Group appoints Frans van Houten, former CEO of Philips, as new member of the Supervisory Board

THE HAGUE, Netherlands, Jan. 19, 2024 /PRNewswire/ -- Affidea Group, the leading pan-European provider of integrated healthcare including advanced diagnostics, out-of-hospital services and centers of excellence, today announces the appointment of Frans van Houten as non-member executive of the Supervisory Board. Frans van Houten, a recognized visionary in the healthcare technology and innovation sectors, will leverage his leadership skills and expertise to significantly enhance Affidea's digital innovation and growth aspirations.

Frans van Houten spent almost 30 years at Royal Philips and is highly regarded for his strategic insights. In his role as CEO, he transformed the organization from a diversified conglomerate to a company focused on health technology solutions. This transformation doubled Philips' organic growth and profitability. Additionally, Frans van Houten currently sits on the board of directors of Novartis, contributing to one of the world's largest pharmaceutical companies and also advises the private equity sector.

Frans van Houten said: "Affidea stands as a fast-growing European healthcare champion, recognized for its innovative spirit, a spirit I am delighted to support. The company's long-standing dedication to improving all aspects of the route of care and improving patient outcomes through technological innovation resonates with mine. My commitment is the seamless integration of cutting-edge patient-centric solutions that promise quality, personalized and efficient healthcare experiences across the continuum. I look forward to collaborating with the Supervisory Board and the management team to unlock Affidea's full growth potential."

Michal Chalaczkiewicz, Chairman of the Supervisory Board of Affidea and Investment Partner at GBL, added: "We are delighted to welcome Frans van Houten to the Supervisory Board of Affidea, joining the other distinguished members. His appointment represents a significant addition ", which embodies GBL's commitment as a shareholder of GBL. Affidea. We look forward to working alongside Frans and drawing on his experience as we build the future path of this exciting journey together with the Affidea and GBL teams."

Guy Blomfield, CEO of Affidea Group and Chairman of the Board of Directors, said: "We warmly welcome Frans to our Supervisory Board. His experience in developing innovative, connected and patient-focused solutions will be relevant to the plans. Affidea's strategic growth strategy. Its track record in digital transformations is particularly important. The company will benefit from its experience in the standardization and optimization of processes and data management, leading to optimal care routes and, progressively, the adoption of solutions of AI".

Fran van Houten's experience in healthcare innovation and advanced technologies aligns with Affidea's ambitions to develop connected, patient-centric solutions, including telehealth services and wearable technologies, aimed at enriching the entire care process. This strategic direction will enable the company's medical professionals to access and respond to patient needs remotely, thereby improving healthcare outcomes.

Frans van Houten joins the Supervisory Board together with Affidea management, GBL representatives and Dimitris Moulavasilis, who joined as a non-executive director in 2022. Dimitris Moulavasilis is the current CEO of Diaverum and former CEO of Affidea.

Affidea is majority owned by GBL (Groupe Bruxelles Lambert), an established investment holding company committed to strong governance and leadership across its business portfolio. GBL is a leading investor in Europe, focused on long-term value creation and with a stable and supportive family shareholder base.

Learn more about Affidea Supervisory Board members at:

About Affidea Group

Affidea Group is Europe's leading integrated healthcare provider, including advanced diagnostics, out-of-hospital services and centers of excellence in orthopedics and oncology care. Founded in 1991, the company operates more than 340 medical centers in 15 countries and serves more than 13 million patients annually. Due to its high standards in patient safety, Affidea is the most awarded medical imaging service provider in Europe. More than 90% of the centers awarded 5 stars on the Eurosafe Star Wall, accredited by the European Society of Radiology in Europe, are Affidea centers.

Logo -

View original content: